Skip to content

Effectiveness of Bupivacaine in Pain Management following Breast Augmentation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN81120207
Enrollment
50
Registered
2007-09-28
Start date
2006-08-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Signs and Symptoms: Pain Signs and Symptoms Procedures for purposes other than remedying health state

Interventions

A blinded member of the team will assess the pain at 2,4 and hours after the operation. Length of hospital stay is also recorded. The data analysis will take place at Countess of Chester Hospital (CO

Sponsors

Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients undergoing breast augmentation 2. For correction of congenital anomaly or asymmetry. This group is usually young population, so usually not associated with co-morbid conditions which might complicate result.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing augmentation following mastectomy or as part of other reconstruction 2. Patients with multiple co-morbidity

Design outcomes

Primary

MeasureTime frame
Is bupivacaine superior than placebo in pain control following breast augmentation?

Secondary

MeasureTime frame
1. Does bupivacaine reduce opiate requirement? 2. Does it reduce hospital stay? 3. Does it reduce the incidence of opiate related adverse effects?

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026